Aviva, Axon in biochip development program
Executive Summary
Biochip company Aviva Biosciences will make a $3.5mm equity investment in Axon Instruments (drug discovery technologies that combine biochips and cell biology) in exchange for an exclusive license to intellectual property and patch clamp biochips.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice